{
    "clinical_study": {
        "@rank": "1421", 
        "arm_group": [
            {
                "arm_group_label": "Flublok", 
                "arm_group_type": "Active Comparator", 
                "description": "Flublok containing 3x45\u00b5g (135\u00b5g total) of rHA0 derived from influenza A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5mL"
            }, 
            {
                "arm_group_label": "Afluria", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Afluria, containing 3x15\u00b5g (45\u00b5g total), of trivalent, inactivated influenza vaccine (licensed IIV) containing influenza antigen derived from A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5mL"
            }
        ], 
        "brief_summary": {
            "textblock": "The hypothesis for this trial is that the incidence of a pre-defined composite of common\n      systemic hypersensitivity adverse events for Flublok recipients is non-inferior to that\n      reported for licensed IIV recipients.  Another hypothesis is that the safety and\n      reactogenicity of Flublok is clinically acceptable, i.e. consistent with the overall safety\n      profiles previously observed with Flublok and with the licensed comparator."
        }, 
        "brief_title": "Comparison of the Safety of Flublok\u00ae Versus Licensed IIV in Healthy, Medically Stable Adults \u2265 50 Years of Age", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "The ACIP recommends that all people aged 6 months and older be immunized to prevent\n      influenza.  Currently the only approved influenza vaccine across the entire age group is\n      inactivated influenza vaccine (IIV).  A Biologics Licensing Application (BLA) for Flublok\n      was approved by the FDA for influenza immunization of adults 18-49 years of age. Additional\n      safety and, ultimately efficacy, data is needed to support use in adults \u226550 years of age,\n      an important age group as adults \u226565 years of age are among those at increased risk of\n      influenza complications."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Ambulatory adults aged 50 years and older\n\n          2. Medically stable, as determined by medical history and targeted physical examination\n             based on medical history, if appropriate\n\n          3. Able to understand and comply with planned study procedures\n\n          4. Provides written informed consent prior to initiation of any study procedure.\n\n        Exclusion Criteria:\n\n          1. Known contraindication to either study vaccine (see product package inserts)\n\n          2. Receipt of any other influenza or other vaccine within 30 days prior to enrollment in\n             this study.\n\n          3. Receipt of any new medication within 30 days prior to enrollment in this study\n\n          4. Plans to participate in any investigation involving an investigational product during\n             this study.\n\n          5. Pre-existence of atopic dermatitis or any other cutaneous disorder that could\n             complicate the evaluation of potential primary endpoints.\n\n          6. Any clinical or social circumstance that in the opinion of the investigator could\n             interfere with compliance with study procedures or interfere with the interpretation\n             of clinical data."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "2639", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825200", 
            "org_study_id": "PSC11"
        }, 
        "intervention": [
            {
                "arm_group_label": "Flublok", 
                "description": "A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age.  Flublok is produced using recombinant technology under serum-free conditions.", 
                "intervention_name": "Flublok", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Afluria", 
                "description": "Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.", 
                "intervention_name": "Afluria", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Influenza", 
        "lastchanged_date": "October 8, 2013", 
        "link": {
            "description": "Related Info", 
            "url": "http://proteinsciences.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85704-1152"
                    }, 
                    "name": "Genova Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coral Gables", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33134"
                    }, 
                    "name": "Clinical Research of South Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Savannah", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31406"
                    }, 
                    "name": "Meridian Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67207"
                    }, 
                    "name": "Heartland Research Associates, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Metairie", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70006"
                    }, 
                    "name": "Benchmark Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auburn", 
                        "country": "United States", 
                        "state": "Maine", 
                        "zip": "04210"
                    }, 
                    "name": "Maine Research Associates, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68164"
                    }, 
                    "name": "Meridian Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89104"
                    }, 
                    "name": "Clinical Research Center of Nevada, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Binghamton", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13901"
                    }, 
                    "name": "Regional Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27612"
                    }, 
                    "name": "Wake Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44122"
                    }, 
                    "name": "Rapid Medical Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75234"
                    }, 
                    "name": "Research Across America"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76135"
                    }, 
                    "name": "Benchmark Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Angelo", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76904"
                    }, 
                    "name": "Benchmark Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of the Safety of Flublok\u00ae Versus Licensed Inactivated Influenza Vaccine in Healthy, Medically Stable Adults \u2265 50 Years of Age", 
        "overall_official": [
            {
                "affiliation": "Meridian Clinical Research", 
                "last_name": "Brandon Essink, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Meridian Clinical Research", 
                "last_name": "Paul Bradley, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Benchmark Research", 
                "last_name": "William Seger, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Benchmark Research", 
                "last_name": "Darrell Herrington, DO", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Benchmark Research", 
                "last_name": "George Bauer, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Regional Clinical Research", 
                "last_name": "Frank Eder, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Wake Research", 
                "last_name": "Treva Tyson, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Maine Research Associates, LLC", 
                "last_name": "Bob Weiss, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinical Research of South Florida", 
                "last_name": "Jeffrey Rosen, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Research Across America", 
                "last_name": "Joe Blumenau, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinical Research Center of Nevada, LLC", 
                "last_name": "Steven Folkerth, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Genova Clinical Research", 
                "last_name": "Leah Schmidt, DO", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Miami Research Associates", 
                "last_name": "Eric Sheldon", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Rapid Medical Research, Inc.", 
                "last_name": "Alan C. Wine, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Heartland Research Associates, LLC", 
                "last_name": "Terry Poling, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Number of participants who experience a pre-defined common systemic hypersensitivity adverse event, including rash, urticaria, swelling or edema through Day 30 post-vaccine administration.", 
            "measure": "Number of participants with common hypersensitivity reactions as measure of safety", 
            "safety_issue": "Yes", 
            "time_frame": "30 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825200"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of events and relatedness of serious adverse events (SAEs) and medically-attended unsolicited AEs (MAEs) and other unsolicited AEs occurring during the 30 days following vaccine administration", 
                "measure": "Number of events and relatedness of SAEs and medically-attended AEs as measure of safety", 
                "safety_issue": "Yes", 
                "time_frame": "30 Days"
            }, 
            {
                "description": "Number of solicited local and systemic events of reactogenicity reported with the help of a memory aid during the seven days following vaccine administration.", 
                "measure": "Number of participants with local and systemic events reported as a measure of safety", 
                "safety_issue": "Yes", 
                "time_frame": "7 Days"
            }, 
            {
                "description": "Number of pre-defined common systemic hypersensitivity adverse events, including rash, urticaria, swelling or non-dependent edema on Day 0 and for Days 0 to 7 following vaccine administration", 
                "measure": "Number of hypersensitivity events reported on Day 0 and Days 0-7 following vaccine administration as a measure of safety", 
                "safety_issue": "Yes", 
                "time_frame": "7 Days"
            }
        ], 
        "source": "Protein Sciences Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Protein Sciences Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}